Published ahead of print on February 11, 2005, doi:10.1164/rccm.200411-1603OE
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 699-706, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200411-1603OE
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Denis A. Mitchison
Medical Microbiology, Department of Cellular and Molecular Medicine, St. George's Hospital Medical School, London, United Kingdom
Correspondence and requests for reprints should be addressed to Denis A. Mitchison, M.B., F.R.C.P., F.R.C. Path, Medical Microbiology, Department of Cellular & Molecular Medicine, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. E-mail: dmitchis{at}sghms.ac.uk
ABSTRACT
Methods for the radiographic diagnosis of tuberculosis have improved from simple fluoroscopy to computerized tomography. Although direct smear examination is still the most widely used bacteriological method of diagnosis, cultural methods with selective liquid media are sensitive and rapid. The use of antituberculosis drugs has changed tuberculosis from a disease with about a 50% mortality, treated by measures to collapse the affected lung lesions and by rest for the patient, to a condition successfully curable by chemotherapy. Key steps in the development of modern chemotherapy regimens were the demonstrations in clinical trials that (1) streptomycin was effective; (2) combination of drugs prevented the emergence of drug-resistant Mycobacterium tuberculosis; (3) chemotherapy under domiciliary conditions was effective and did not put family members at risk of infection; (4) patient compliance could be assisted by fully supervised intermittent regimens, or more effectively, by (5) shortening treatment by the introduction of rifampin and pyrazinamide, the two most potent sterilizing drugs, into the regimens. Regimens were divided into an initial intensive phase, while bacterial populations were high, and a longer continuation phase to complete sterilization. Pyrazinamide was shown to sterilize only in the intensive phase. The treatment of nonpulmonary tuberculosis followed the same plan, but when bacterial populations are low, fewer drugs are required in combination.
This article has been cited by other articles:

|
 |

|
 |
 
A. Grant, P. Gothard, and G. Thwaites
Managing drug resistant tuberculosis
BMJ,
August 28, 2008;
337(aug28_1):
a1110 - a1110.
[Full Text]
|
 |
|

|
 |

|
 |
 
M. H. Baumann, R. Nolan, M. Petrini, Y. C. G. Lee, R. W. Light, and E. Schneider
Pleural Tuberculosis in the United States: Incidence and Drug Resistance
Chest,
April 1, 2007;
131(4):
1125 - 1132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ewer, K. A. Millington, J. J. Deeks, L. Alvarez, G. Bryant, and A. Lalvani
Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure to Mycobacterium tuberculosis
Am. J. Respir. Crit. Care Med.,
October 1, 2006;
174(7):
831 - 839.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. W. Yew and C. C. Leung
Prognostic significance of early weight gain in underweight patients with tuberculosis.
Am. J. Respir. Crit. Care Med.,
August 1, 2006;
174(3):
236 - 237.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Marais, R. P. Gie, H. S. Schaaf, N. Beyers, P. R. Donald, and J. R. Starke
Childhood Pulmonary Tuberculosis: Old Wisdom and New Challenges
Am. J. Respir. Crit. Care Med.,
May 15, 2006;
173(10):
1078 - 1090.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society
|
|
|